Yudi Li

Yudi Li

Auto-generated profile, based on publicly available information

Yudi Li

Department of Neurology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518000, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
ZDZihao Deng
Zihao Deng
YLYudi Li
Yudi Li
WCWenjun Chi
Wenjun Chi
WZWanzhou Zhang
Wanzhou Zhang
FLFangming Li
Fangming Li
LLLing Li
Ling Li
Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder clinically characterized by memory decline, cognitive dysfunction, language impairment, deterioration of visuospatial skills, and personality changes. Pathologically, AD is marked by the deposition of β-amyloid (Aβ) plaques in the brain, the formation of neurofibrillary tangles, and progressive neuronal loss. Recent research has highlighted transfer RNA (tRNA)-derived small RNAs (tsRNAs) as crucial regulators in various biological processes; however, their roles in the pathophysiology of AD remain largely unexplored. The erythropoietin-producing hepatocellular (Eph) receptor family has recently drawn attention in the study of neurodegenerative diseases due to their role in regulating critical processes, including cell migration, neural development, angiogenesis, and tumor formation. This study aimed to investigate specific tsRNAs associated with AD by performing RNA sequencing on the cortex of APP/PS1 transgenic mice and to explore the relationship between tsRNAs and their target genes within the Eph receptor family, thereby elucidating insights into the specific regulatory functions of these molecules. Eight-month-old male C57BL/6 and APP/PS1 transgenic mice were used in the study. BV-2 and HT22 cells were cultured and treated with Aβ25-35 at concentrations ranging from 0 µM to 40 µM. RNA was extracted from cortical tissues, and tRNA-derived fragments were analyzed after pre-treatment to remove RNA modifications. Differential expression of tRFs and tiRNAs was identified through sequencing, followed by bioinformatics analysis of target genes using TargetScan and miRanda. Transfection of BV-2 and HT22 cells with EphA7-siRNA and tRFAla-AGC-3-M8-mimic was conducted, and their interaction was validated using dual-luciferase reporter assays. Protein expression levels were assessed by western blotting and immunofluorescence. Statistical analyses were performed using R and GraphPad Prism, with significance set at p < 0.05. We identified for the first time that EphA7 expression is upregulated in aggregated microglia and neuronal cells in the dentate gyrus region of the hippocampus, with increased phosphorylation of ERK1/2 and p70S6K in AD. This upregulation occurred following the downregulation of tRFAla-AGC-3-M8 due to Aβ stimulation and was confirmed via in vitro experiments. By inhibiting EphA7 expression and increasing tRFAla-AGC-3-M8 expression, we suppressed the ERK1/2-p70S6K signaling pathway in BV-2 and HT22 cells. This intervention alleviated neuronal damage and tau hyperphosphorylation in HT22 cells and reduced the M1-type polarization state of BV-2 cells induced by Aβ25-35 (see Graphical Abstract). This study clarifies the specific role of tRFAla-AGC-3-M8 in AD pathology and offers a promising target for therapeutic interventions.

1 January 2024 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
YLYudi Li
Yudi Li
LLLing Li
Ling Li
JLJie Li
Jie Li
XHXiongjun He
Xiongjun He
KLkaifeng li
kaifeng li
YLYajie Liu
Yajie Liu
The novel coronavirus disease 2019 (COVID‐19) causes severe respiratory illness and is involved in ischemic stroke. Aimed to investigate the inflammatory markers and possible prognosis of COVID‐19‐related ischemic stroke in a special outbreak period after lifting of COVID‐19 control measures in China, we conducted a multicenter retrospective analysis in southern China at three centers in Shenzhen. We included patients diagnosed with acute ischemic stroke or transient ischemic attack after infection with COVID‐19 as the COVID‐19‐related ischemic stroke group and those only diagnosed with acute ischemic stroke or transient ischemic attack as the control group. In this study, the proportion of female patients, admission heart rate, and comorbid coronary heart disease and the proportion of cryptogenic stroke were higher, while the history of prior stroke was lower in the COVID‐19‐related ischemic stroke group. The COVID‐19‐related ischemic stroke group also exhibited elevated levels of monocytes, fibrinogen, alanine aminotransferase, direct bilirubin, monocyte‐to‐lymphocyte ratio (MLR), and fibrinogen‐to‐albumin ratio (FAR) but decreased levels of lymphocytes, albumin, and high‐density lipoprotein. However, there were no statistically significant differences in the modified Rankin scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and mortality rate between the two groups at discharge. Our study is the first to show the alteration in inflammatory markers but no difference in discharge prognosis between the non‐COVID‐19 and the COVID‐19‐related ischemic stroke patients, during China’s COVID‐19 relaxation period.